Endogenous Opioid Activity As the Mechanism of Action for Mitragyna Speciosa (Kratom): The Current State of the Evidence

Overview

Journal Adv Neurobiol

Publisher Springer

Date 2024 Jun 14

PMID 38874729

Authors

Adina Bowe

Patrick L Kerr

Affiliations

Soon will be listed here.

Abstract

Kratom (Mitragyna speciosa) is a substance derived from botanical compounds native to Southeast Asia. This substance has been cultivated predominantly in Thailand, Malaysia, Vietnam, and Myanmar, where it has historically been used in traditional medicine as a near panacea for several health problems. Such ritualistic use of kratom has been present for centuries; however, recreational use appears to have increased globally, especially in the United States. Pharmacodynamic and pharmacokinetic studies have found that kratom demonstrates a unique parabolic, dose-dependent pattern of effects ranging from stimulation to opioid and analgesic effects. Pharmacological research indicates that kratom is both a mu opioid receptor (μ-OR; MOR) and a kappa opioid receptor (κ-OR; KOR) agonist, which mediates its analgesic effects. Other research suggests that kratom may simultaneously act on dopaminergic and serotonergic receptors, which mediate its stimulant effects. This chapter reviews the literature related to the structural, functional, and cultural characteristics of kratom use. We begin with an overview of current and historical patterns of kratom, followed by a review of data on the pharmacodynamics and pharmacokinetics of kratom thus far.

References

Ahmad K, Aziz Z . Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. J Ethnopharmacol. 2012; 141(1):446-50. DOI: 10.1016/j.jep.2012.03.009. View

Anwar M, Law R, Schier J . Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers - United States, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016; 65(29):748-9. DOI: 10.15585/mmwr.mm6529a4. View

Babu K, McCurdy C, Boyer E . Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila). 2008; 46(2):146-52. DOI: 10.1080/15563650701241795. View

BECKETT A, SHELLARD E, Phillipson J, Lee C . The Mitragyna species of Asia. VII. Indole alkaloids from the leaves of Mitragyna speciosa Korth. Planta Med. 1966; 14(3):277-88. DOI: 10.1055/s-0028-1100055. View

Bowe A, Kerr P . A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management. J Psychoactive Drugs. 2020; 52(5):447-452. DOI: 10.1080/02791072.2020.1773586. View

Boyer E, Babu K, Adkins J, McCurdy C, Halpern J . Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008; 103(6):1048-50. PMC: 3670991. DOI: 10.1111/j.1360-0443.2008.02209.x. View

Braley C, Hondrogiannis E . Differentiation of Commercially Available Kratom by Purported Country of Origin using Inductively Coupled Plasma-Mass Spectrometry. J Forensic Sci. 2019; 65(2):428-437. DOI: 10.1111/1556-4029.14201. View

Brown P, Lund J, Murch S . A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: Implications for products sold as kratom. J Ethnopharmacol. 2017; 202:302-325. DOI: 10.1016/j.jep.2017.03.020. View

Carroll J, Marshall B, Rich J, Green T . Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study. Int J Drug Policy. 2017; 46:136-145. PMC: 5560423. DOI: 10.1016/j.drugpo.2017.05.023. View

10.

Chan K, Pakiam C, Rahim R . Psychoactive plant abuse: the identification of mitragynine in ketum and in ketum preparations. Bull Narc. 2011; 57(1-2):249-56. View

11.

Chear N, Leon F, Sharma A, Kanumuri S, Zwolinski G, Abboud K . Exploring the Chemistry of Alkaloids from Malaysian (Kratom) and the Role of Oxindoles on Human Opioid Receptors. J Nat Prod. 2021; 84(4):1034-1043. PMC: 8693998. DOI: 10.1021/acs.jnatprod.0c01055. View

12.

Davidson L, Rawat M, Stojanovski S, Chandrasekharan P . Natural drugs, not so natural effects: Neonatal abstinence syndrome secondary to 'kratom'. J Neonatal Perinatal Med. 2018; 12(1):109-112. PMC: 6484255. DOI: 10.3233/NPM-1863. View

13.

Eggleston W, Stoppacher R, Suen K, Marraffa J, Nelson L . Kratom Use and Toxicities in the United States. Pharmacotherapy. 2019; 39(7):775-777. DOI: 10.1002/phar.2280. View

14.

Eldridge W, Foster C, Wyble L . Neonatal Abstinence Syndrome Due to Maternal Kratom Use. Pediatrics. 2018; 142(6). DOI: 10.1542/peds.2018-1839. View

15.

Forrester M . Kratom exposures reported to Texas poison centers. J Addict Dis. 2013; 32(4):396-400. DOI: 10.1080/10550887.2013.854153. View

16.

Giovannitti Jr J, Thoms S, Crawford J . Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015; 62(1):31-9. PMC: 4389556. DOI: 10.2344/0003-3006-62.1.31. View

17.

Griffin O, Webb M . The Scheduling of Kratom and Selective Use of Data. J Psychoactive Drugs. 2017; 50(2):114-120. DOI: 10.1080/02791072.2017.1371363. View

18.

Grundmann O . Patterns of Kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend. 2017; 176:63-70. DOI: 10.1016/j.drugalcdep.2017.03.007. View

19.

Hassan Z, Muzaimi M, Navaratnam V, Yusoff N, Suhaimi F, Vadivelu R . From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2012; 37(2):138-51. DOI: 10.1016/j.neubiorev.2012.11.012. View

20.

Hazim A, Ramanathan S, Parthasarathy S, Muzaimi M, Mansor S . Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats. J Physiol Sci. 2014; 64(3):161-9. PMC: 10717818. DOI: 10.1007/s12576-014-0304-0. View